Arcutis Biotherapeutics, Inc.
ARQTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. At a $3.07B market cap, Arcutis Biotherapeutics, Inc. ranks as a mid-cap company within healthcare. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Market Cap
$3.07B
Beta
1.50
P/E (TTM)
110.86
P/E (Fwd)
18.71
EPS (TTM)
$0.22
EPS (Fwd)
$1.30
ROE
15.9%
ROA
5.1%
Cash
$238.6M
Total Debt
$114.1M
Free CF
$21.7M
52W Change
36.0%
Annual Financials
Cash vs Debt
Where ARQT stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ARQT finished 3.77% below its 150-day moving average ($24.68) and 7.30% below its 200-day moving average ($25.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARQT overbought or oversold?
At the September 2, 2026 close, ARQT's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $238.6M in cash comfortably exceeding the $114.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $21.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 15.9%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $3.7M (2022) to $376.1M (2025), reflecting a 10103% increase over the period.
A beta of 1.50 means ARQT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Arcutis Biotherapeutics, Inc.'s trajectory.